-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
Evidence-based therapy for the ANCA associated vasculitides: what do the trials show so far?
Lovesh Dyall , Dimitrios Chanouzas & Matthew David Morgan
Clinical Trail Outcomes: Clinical Investigation
-
When should the sequential parallel comparison design be used in clinical trials?
Lee Baer, Anastasia Ivanova
Clinical Trail Methodology: Clinical Investigation
-
When should the sequential parallel comparison design be used in clinical trials?
Lee Baer, Anastasia Ivanova
Clinical Trail Methodology: Clinical Investigation
-
When should the sequential parallel comparison design be used in clinical trials?
Lee Baer, Anastasia Ivanova
Clinical Trail Methodology: Clinical Investigation
-
When should the sequential parallel comparison design be used in clinical trials?
Lee Baer, Anastasia Ivanova
Clinical Trail Methodology: Clinical Investigation
-
When should the sequential parallel comparison design be used in clinical trials?
Lee Baer, Anastasia Ivanova
Clinical Trail Methodology: Clinical Investigation
-
When should the sequential parallel comparison design be used in clinical trials?
Lee Baer, Anastasia Ivanova
Clinical Trail Methodology: Clinical Investigation
-
When should the sequential parallel comparison design be used in clinical trials?
Lee Baer, Anastasia Ivanova
Clinical Trail Methodology: Clinical Investigation
-
When should the sequential parallel comparison design be used in clinical trials?
Lee Baer, Anastasia Ivanova
Clinical Trail Methodology: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Ricard Cervera, Gerard Espinosa
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Key features of the EXPANSE clinical program for apixaban in the prevention and treatment of thrombotic disorders
Nadia Rosencher, Paul Zufferey, Silvy Laporte, Patrick Mismetti
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation
-
Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia
Brad Spellberg, Roger J Lewis, Helen W Boucher,Eric P Brass
Review Article: Clinical Investigation